Identification

Name
Pentazocine
Accession Number
DB00652  (APRD01173)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

Structure
Thumb
Synonyms
  • Pentazocin
  • Pentazocina
  • Pentazocine
  • Pentazocinum
External IDs
CS 350 / NIH 7958 / Win 20228
Product Ingredients
IngredientUNIICASInChI Key
Pentazocine HydrochlorideA36BXO4PPX64024-15-3OQGYMIIFOSJQSF-DTOXXUQYSA-N
Pentazocine Lactate1P2XIB510O17146-95-1QNLDTXPVZPRSAM-DTOXXUQYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines2010-08-012017-01-25Us
TalwinTablet50 mgOralSanofi Aventis1970-12-31Not applicableCanada
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2010-10-122017-08-11Us
TalwinSolution30 mgIntramuscular; Intravenous; SubcutaneousPfizer2002-11-01Not applicableCanada
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2005-11-18Not applicableUs
Talwin - Liq 30mg/mlLiquid30 mgIntramuscular; Intravenous; SubcutaneousSanofi Synthelabo1967-12-31Not applicableCanada
International/Other Brands
Fortal (Sanofi-Aventis) / Fortral (Sanofi-Aventis) / Fortwin (Terapia) / Pangon (L.B.S.) / Pentagin (Daiichi Sankyo) / Sosegon (Sanofi-Aventis) / Stopain (Beximco) / Talwin PX (Sanofi-Aventis)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pentazocine and naloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc1997-01-212017-09-21Us
Pentazocine and naloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralActavis Pharma Company1997-01-21Not applicableUs
Pentazocine and NaloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralGolden State Medical Supply2000-03-24Not applicableUs
Pentazocine and naloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralbryant ranch prepack1997-01-21Not applicableUs
Pentazocine and naloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralPd Rx Pharmaceuticals, Inc.1997-01-21Not applicableUs
Pentazocine and naloxonePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralKeltman Pharmaceuticals Inc.2009-07-21Not applicableUs
Pentazocine HCl and AcetaminophenPentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1)TabletOralRebel Distributors2000-03-24Not applicableUs
Pentazocine HCl and Naloxone HClPentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralStat Rx USA1997-01-21Not applicableUs
Pentazocine Hydrochloride and AcetaminophenPentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1)TabletOralGavis Pharmaceuticals, LLC.2011-05-11Not applicableUs
Pentazocine Hydrochloride and Naloxone HydrochloridePentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)TabletOralDirectrx2014-01-01Not applicableUs
Categories
UNII
768DQ5A5AI
CAS number
359-83-1
Weight
Average: 285.4238
Monoisotopic: 285.209264491
Chemical Formula
C19H27NO
InChI Key
VOKSWYLNZZRQPF-GDIGMMSISA-N
InChI
InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
IUPAC Name
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6-trien-4-ol
SMILES
C[[email protected]]1[[email protected]]2CC3=CC=C(O)C=C3[[email protected]]1(C)CCN2CC=C(C)C

Pharmacology

Indication

For the relief of moderate to severe pain.

Structured Indications
Pharmacodynamics

Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.

Mechanism of action

The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.

TargetActionsOrganism
AMu-type opioid receptor
antagonist
Human
AKappa-type opioid receptor
agonist
Human
ASigma non-opioid intracellular receptor 1
agonist
Human
Absorption

Well absorbed from the gastro-intestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic

Route of elimination
Not Available
Half life

2 to 3 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pentazocine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.Approved, Investigational
AlaproclatePentazocine may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Pentazocine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Pentazocine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentazocine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Pentazocine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone.Investigational, Vet Approved
AzelastinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol.Approved
BezitramidePentazocine may decrease the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Pentazocine.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Pentazocine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bupivacaine.Approved, Investigational
BuprenorphinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pentazocine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pentazocine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Pentazocine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Pentazocine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cinchocaine.Approved, Vet Approved
CitalopramPentazocine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.Approved
CocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pentazocine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dapiprazole.Approved
DapoxetinePentazocine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.Approved
DesvenlafaxinePentazocine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Pentazocine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pentazocine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drotebanol.Experimental, Illicit
DuloxetinePentazocine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eltanolone.Investigational
EluxadolinePentazocine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Pentazocine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.Approved
EscitalopramPentazocine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Pentazocine.Experimental
EthanolPentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentazocine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate.Approved
EtoperidonePentazocine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Pentazocine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam.Approved, Illicit
FluoxetinePentazocine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Pentazocine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentazocine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Pentazocine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentazocine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pentazocine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pentazocine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Pentazocine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.Approved
IndalpinePentazocine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Pentazocine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isosorbide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranPentazocine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Pentazocine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Pentazocine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Pentazocine.Investigational
MephentermineMephentermine may increase the analgesic activities of Pentazocine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pentazocine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.Approved
MethotrimeprazinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Pentazocine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Pentazocine.Approved, Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Pentazocine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.Approved
MeticraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.Approved
MetyrosinePentazocine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit, Investigational
MilnacipranPentazocine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Investigational
MirtazapinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Pentazocine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Pentazocine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pentazocine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nalbuphine.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodonePentazocine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nialamide.Withdrawn
NicomorphinePentazocine may decrease the analgesic activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Opium.Approved, Illicit
OrphenadrinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Pentazocine.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Pentazocine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pentazocine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.Approved
ParaldehydePentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pargyline.Approved
ParoxetinePentazocine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Penfluridol.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pentazocine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pentazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Pentazocine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.Approved, Vet Approved
PramipexolePentazocine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentazocine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Pentazocine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Pentazocine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Pentazocine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Pentazocine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.Approved, Investigational
RamosetronPentazocine may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Pentazocine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Romifidine.Vet Approved
RopinirolePentazocine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ropivacaine.Approved
RotigotinePentazocine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pentazocine.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralinePentazocine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Pentazocine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sultopride.Experimental
SuvorexantPentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin.Investigational
ThalidomidePentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Pentazocine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pentazocine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pentazocine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Pentazocine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.Approved
VenlafaxinePentazocine may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.Approved
ZimelidinePentazocine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zolazepam.Vet Approved
ZolpidemPentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14790
KEGG Drug
D00498
KEGG Compound
C07421
PubChem Compound
441278
PubChem Substance
46506363
ChemSpider
390041
BindingDB
50001028
ChEBI
7982
ChEMBL
CHEMBL560
Therapeutic Targets Database
DAP000356
PharmGKB
PA164744326
IUPHAR
1606
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pentazocine
ATC Codes
N02AD01 — Pentazocine
AHFS Codes
  • 28:08.12 — Opiate Partial Agonists
MSDS
Download (48.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentTreatment of Menopausal Hot Flashes1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes / Schizoaffective Disorders1
4Unknown StatusTreatmentAnaesthesia therapy / Pregnancy Termination1
Not AvailableCompletedTreatmentHeadaches / Migraines1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous30 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous30 mg
TabletOral50 mg
LiquidIntramuscular; Intravenous; Subcutaneous30 mg
Prices
Unit descriptionCostUnit
Talwin 30 mg/ml vial14.78USD ml
Talwin 30 mg/ml ampul4.86USD ml
Talwin 30 mg/ml1.64USD ml
Talwin 50 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)146.3 °CPhysProp
logP4.64DAYLIGHT (1999)
pKa8.88SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.122 mg/mLALOGPS
logP4.44ALOGPS
logP3.89ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)7.59ChemAxon
pKa (Strongest Basic)12.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.8 m3·mol-1ChemAxon
Polarizability33.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9769
Caco-2 permeable+0.7902
P-glycoprotein substrateSubstrate0.9014
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6975
Renal organic cation transporterInhibitor0.6982
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7819
CYP450 1A2 substrateInhibitor0.5886
CYP450 2C9 inhibitorNon-inhibitor0.8321
CYP450 2D6 inhibitorInhibitor0.8147
CYP450 2C19 inhibitorNon-inhibitor0.8585
CYP450 3A4 inhibitorNon-inhibitor0.8155
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.778
Ames testNon AMES toxic0.8231
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity2.4411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6301
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2,6-dimethyl-3-benzazocines. These are aromatic compounds containing a 6,7-benzomorphan skeleton, which is substituted by methyl group at the 2- and 6-positions.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
6,7-benzomorphans
Sub Class
2,6-dimethyl-3-benzazocines
Direct Parent
2,6-dimethyl-3-benzazocines
Alternative Parents
4-hydroxy-6,7-benzomorphans / Benzazocines / Tetralins / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 1 more
Substituents
2,6-dimethyl-3-benzazocine / 4-hydroxy-6,7-benzomorphan / Benzazocine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Tertiary amine / Tertiary aliphatic amine
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzazocine (CHEBI:7982)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72. [PubMed:3419842]
  2. Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44. [PubMed:6094791]
  3. Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10. [PubMed:8042002]
  4. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334]
  5. Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82. [PubMed:2286420]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
Gene Name
SIGMAR1
Uniprot ID
Q99720
Uniprot Name
Sigma non-opioid intracellular receptor 1
Molecular Weight
25127.52 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]
  2. Colabufo NA, Contino M, Inglese C, Niso M, Perrone R, Roperto S, Roperto F: In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):161-71. [PubMed:20021350]
  3. Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB: Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94. [PubMed:17898305]
  4. Mamolo MG, Zampieri D, Zanette C, Florio C, Collina S, Urbano M, Azzolina O, Vio L: Substituted benzylaminoalkylindoles with preference for the sigma2 binding site. Eur J Med Chem. 2008 Oct;43(10):2073-81. Epub 2007 Sep 26. [PubMed:18069094]
  5. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, Ruoho AE: Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007 Oct;72(4):921-33. Epub 2007 Jul 10. [PubMed:17622576]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49